QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module IX — Special Situations and Difficult Signals

Test your understanding of the concepts covered by GVP Module IX: Special Situations and Difficult Signals.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An inspection finds that a serious signal was closed solely because only three cases had been reported. What is the principal weakness?

The company should never close a signal with fewer than ten cases The company treated case count as a decision rule instead of assessing credibility, phenotype, alternatives and potential consequence The company should have automatically confirmed the signal The company should have relied only on statistical disproportionality

Question 2 of 10 Several apparently separate event terms may reflect one underlying biological mechanism. What is the appropriate approach?

Always assess each event term separately to avoid bias Always aggregate all related event terms into one broad signal Determine whether the events are genuinely related, document the rationale, and balance broader detection against loss of clinical specificity Exclude the less frequently reported terms from assessment

Question 3 of 10 A newly authorised product has very limited exposure and no stable quantitative signal. Which interpretation is most appropriate?

Limited exposure demonstrates that the product has a low risk The absence of a quantitative pattern may reflect limited power to observe the event The product should not be monitored until sufficient exposure accumulates Only disproportionality analysis is appropriate during early use

Question 4 of 10 Which statement best describes appropriate QPPV oversight of a materially important difficult signal?

The QPPV must personally perform every statistical and clinical analysis The QPPV should have sufficient visibility to understand the question, evidence, uncertainty, decision and adequacy of follow-up The QPPV needs visibility only after a regulatory procedure begins The QPPV's role ends once a multidisciplinary team is appointed

Question 5 of 10 Several plausible explanations exist for an observed event, including the underlying disease, a concomitant medicine and an environmental exposure. What is the most mature analytical approach?

Assess only whether the product is temporally associated with the event Choose the most concerning hypothesis for precautionary purposes and omit the alternatives Explicitly define competing hypotheses and identify evidence that would discriminate among them Treat all hypotheses as equally likely until a randomized trial is available

Question 6 of 10 A database shows a sharp increase in a preferred term after a MedDRA version change and search-strategy modification. What should be done before interpreting the trend as a safety change?

Assume the product risk increased because the report count increased Ignore the trend because coding changes cannot affect signal detection Assess and document whether the methodological changes could explain part of the apparent increase Revert all cases to the previous coding without further analysis

Question 7 of 10 Another national regulator identifies a safety concern for a product. What should the MAH do in the EU context?

Adopt the other authority's conclusion without further assessment Ignore the concern because it originated outside the EU Assess the underlying evidence and its applicability to European populations, indications, exposure and regulatory context Wait for the other authority to mandate an EU action

Question 8 of 10 An adverse reaction is already listed, but a new cluster suggests a substantially shorter latency and greater severity in a particular population. What should the company do?

Close the signal because listedness prevents further signal management Assess whether the new characteristics materially change understanding or management of the risk Remove the event from signal review because it is already known Assume the finding is a class effect and take no product-specific action

Question 9 of 10 For a common event, which question is generally most relevant when assessing whether a new product-associated risk exists?

Whether the event appears in any case report at all Whether the observed frequency, severity, timing or phenotype differs from an appropriate background expectation Whether the event is already common in the general population Whether the event is listed for another product

Question 10 of 10 A publication reports a case series suggesting a product-event association. What is the correct treatment of the publication?

Treat publication in a peer-reviewed source as proof of causality Ignore it unless the same association appears in spontaneous-reporting statistics Evaluate the quality, relevance and limitations of the underlying evidence Give it less weight than all spontaneous reports because it is not regulatory data

Knowledge Assessment: GVP Module IX — Special Situations and Difficult Signals

Cookie Settings